8.1 Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements

Informed Consent Elements, Process & Ongoing Consent / Re-Consent Requirements

Exam scope note: This section cites national regulations (for example US Code of Federal Regulations provisions) because they shape day-to-day practice. ACRP states the ACRP-CP exam is referenced only to ICH Guidelines and that no country-specific framework is tested. Treat those citations as professional context; the provision examined here is ICH E6(R3) Principle 2 and Annex 1 section 2.8 (Informed Consent of Trial Participants).

Quick Reference: Under 21 CFR 50.20, 45 CFR 46.116, and ICH GCP E6(R3) Annex 1 section 2.8, informed consent is an essential ethical and legal prerequisite for human subject research. It is defined not as a single signature event, but as an ongoing educational dialogue between the investigator/research team and the participant. The Informed Consent Form (ICF) must be written in language understandable to the participant, contain all 8 mandatory basic elements (plus applicable additional elements), contain zero exculpatory language, and be formally approved by the Institutional Review Board (IRB) / Independent Ethics Committee (IEC) prior to use.

For candidates preparing for the ACRP-CP (ACRP Certified Professional) exam, informed consent represents one of the most heavily tested domains under Ethical and Participant Safety Considerations. Exam scenarios frequently challenge your ability to identify regulatory omissions, resolve non-English translation requirements, manage impartial witnesses for illiterate subjects, and execute compliant re-consent workflows.

---

1. The 8 Mandatory Basic Elements of Informed Consent

Both US Food and Drug Administration (FDA) regulations (21 CFR 50.25(a)) and the International Council for Harmonisation (ICH E6(R3) Annex 1 2.8) mandate that every informed consent document provide eight core elements of information to prospective participants prior to enrollment.

---

2. Additional Elements of Informed Consent

Under 21 CFR 50.25(b) and the Revised Common Rule (45 CFR 46.116(c)), when appropriate, one or more of the following additional elements must also be provided in the ICF:

1. Unforeseeable Risks: A statement that the particular treatment or procedure may involve risks to the subject (or to the embryo or fetus, if the subject is or may become pregnant) that are currently unforeseeable.
2. Involuntary Termination by Investigator: Anticipated circumstances under which the subject's participation may be terminated by the investigator without regard to the subject's consent (e.g., progressive disease, unacceptable toxicity, non-compliance with study visits).
3. Additional Costs to Subject: Any additional costs to the subject that may result from participation in the research (e.g., travel, copayments for standard-of-care tests not covered by the sponsor).
4. Orderly Withdrawal Procedures: The consequences of a subject's decision to withdraw from the research and procedures for orderly and safe termination of participation (e.g., drug tapering, safety follow-up visit).
5. Significant New Findings: A statement that significant new findings developed during the course of the research that may relate to the subject's willingness to continue participation will be provided to the subject in a timely manner (the regulatory basis for re-consent).
6. Approximate Number of Subjects: The approximate total number of subjects involved in the study globally and at the local site.
7. Biospecimen Commercialization & Genetic Data (Common Rule / Modern GCP):
   • A statement that the subject's biospecimens (even if identifiers are removed) may be used for commercial profit and whether the subject will share in this profit.
   • Whether clinically relevant research results, including individual research results, will be returned to subjects.
   • Whether the research will or might include whole genome sequencing.

Mandatory ClinicalTrials.gov Statement (21 CFR 50.25(c))

For all applicable FDA-regulated clinical trials, the ICF must include the exact statutory language verbatim:

"A description of this clinical trial will be available on http://www.ClinicalTrials.gov, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time."

---

3. Strict Prohibition of Exculpatory Language (21 CFR 50.20 & ICH E6(R3) Annex 1 2.8)

One of the most critical legal protections in clinical research is the absolute bar on exculpatory language.

┌───────────────────────────────────────────────────────────────────────────┐
│                     EXCULPATORY LANGUAGE REGULATION                      │
├───────────────────────────────────────────────────────────────────────────┤
│  21 CFR 50.20 & ICH E6(R3) Annex 1 2.8:                                            │
│  "No informed consent, whether oral or written, may include any           │
│  exculpatory language through which the subject or the representative     │
│  is made to waive or appear to waive any of the subject's legal rights,   │
│  or releases or appears to release the investigator, the sponsor, the     │
│  institution, or its agents from liability for negligence."              │
└───────────────────────────────────────────────────────────────────────────┘

Compliant vs. Prohibited Language Comparison

Exam Key Point: On the ACRP-CP exam, any clause stating that the subject "waives claims," "releases the site from liability," or "acknowledges that the hospital is not responsible for medical errors/negligence" is strictly illegal exculpatory language and will result in an immediate audit citation.

---

4. The Informed Consent Process as an Educational Dialogue

Informed consent is a continuous communication process, not a one-time paper-signing event.

┌───────────────────────────────────────────────────────────────────────────┐
│                      THE 5-PHASE CONSENT PROCESS                          │
├───────────────────────────────────────────────────────────────────────────┤
│  1. INFORMATION PRESENTATION: Provide approved ICF in understandable lang  │
│  2. ADEQUATE TIME: Allow participant sufficient time to read & consult    │
│  3. COMPREHENSION VERIFICATION: Ask open-ended questions to test grasp     │
│  4. VOLUNTARY SIGNATURE: Subject & person obtaining consent sign & date   │
│  5. ONGOING DIALOGUE: Provide copy, discuss updates, re-consent if needed │
└───────────────────────────────────────────────────────────────────────────┘

Core Operational Principles:

1. Language Understandability: The ICF must be written at a reading level appropriate for the target population (typically 6th to 8th-grade reading level), avoiding complex technical jargon.
2. Adequate Time & Environment: The subject must be given ample time to read the ICF, discuss it with family members, personal physicians, or trusted advisors, and formulate questions. Consent should never be rushed in a pre-operative holding area or immediately prior to a scheduled procedure.
3. Mitigating Coercion and Undue Influence (ICH E6(R3) Annex 1 2.8):
   • Neither the investigator nor the trial staff should coerce or unduly influence a subject to participate.
   • In vulnerable hierarchical settings (e.g., medical students recruited by their professor, employees recruited by a supervisor, prisoners, or terminally ill patients), special protections must prevent undue pressure.
   • Financial Compensation: Payment for participation must be prorated across study visits rather than contingent upon completing the entire trial. Excessive or completion-only lump sums constitute undue influence.
4. Verification of Understanding: The person obtaining consent must verify comprehension using open-ended questions (e.g., "Can you explain in your own words what procedures you will undergo at Visit 2?" or "What will happen if you decide to stop taking the study medication next month?").
5. Proper Execution & Copy Provision (ICH E6(R3) Annex 1 2.8): Both the subject (or Legally Authorized Representative) and the person obtaining consent must personally sign and self-date the ICF. The participant must be provided a signed and dated copy of the ICF immediately upon execution, and this must be documented in the medical source record.

---

5. Special Consent Populations & Operational Procedures

A. Consenting Non-English Speaking Participants

When enrolling prospective participants who do not speak or read English, federal regulations (21 CFR 50.27) and GCP require specific procedural pathways:

                  ┌─────────────────────────────────────────┐
                  │ NON-ENGLISH SPEAKING SUBJECT CANDIDATE  │
                  └────────────────────┬────────────────────┘
                                       │
            ┌──────────────────────────┴──────────────────────────┐
            ▼                                                     ▼
┌───────────────────────────────┐     ┌─────────────────────────────────────────┐
│ PREFERRED METHOD: FULL ICF    │     │ ALTERNATIVE METHOD: SHORT FORM PROCESS  │
│ • IRB-approved translation    │     │ • Unexpected non-English speaker        │
│   of the complete ICF         │     │ • Written Short Form in subject's lang  │
│ • Qualified Medical Interp.   │     │ • IRB-approved English ICF as Summary   │
│ • Subject signs translated ICF│     │ • Impartial bilingual witness present   │
└───────────────────────────────┘     └────────────────────┬────────────────────┘
                                                           │
                                      ┌────────────────────┴────────────────────┐
                                      ▼                                         ▼
                            [ SHORT FORM DOCUMENT ]                   [ WRITTEN SUMMARY (EN ICF) ]
                            • Signed by: Subject                      • Signed by: Person Obtaining
                            • Signed by: Impartial Witness            • Signed by: Impartial Witness
                            • Subject receives copy                   • Subject receives copy

1. Full Translated Consent Form (Preferred Method)

• Used when enrolling from a recognized non-English speaking population (e.g., a clinical trial in a predominantly Spanish-speaking community).
• The entire IRB-approved English ICF is translated into the participant's primary language by a certified translator, and the translated version is formally approved by the IRB prior to use.
• A qualified medical interpreter facilitates the discussion. Family members or friends should never serve as official medical translators due to confidentiality and clinical accuracy risks.
• The participant reads, understands, signs, and dates the translated ICF.

2. Short Form Consent Process (21 CFR 50.27(b)(2) / 45 CFR 46.117(b)(2))

• Used when an unexpected non-English speaking patient meets eligibility criteria for a study with potential direct benefit, and an IRB-approved fully translated ICF is not immediately available.
• Required Elements for the Short Form Process:
  1. Short Form Document: A brief written document in the subject's native language stating that the elements of informed consent have been presented orally.
  2. Written Summary: The full IRB-approved English ICF serves as the written summary of what is orally presented.
  3. Impartial Witness: A fluent bilingual witness (who can be the certified medical interpreter, provided they are not part of the research team) must be physically present for the entire oral presentation.
  4. Signatures Breakdown:
     • Short Form Document: Signed and dated by the Subject (or LAR) and the Impartial Witness.
     • Written Summary (English ICF): Signed and dated by the Person Obtaining Consent and the Impartial Witness.
     • The Subject does not sign the English Summary (since they cannot read English).
  5. Copies Provided: The subject must receive copies of both the signed Short Form and the signed Written Summary.
  6. Follow-Up Requirement: The site must promptly translate the full ICF, obtain IRB approval, and provide the fully translated ICF to the subject.

---

B. Consenting Illiterate or Visually Impaired Participants (ICH E6(R3) Annex 1 2.8)

When a subject is competent to give consent but is illiterate, cannot read due to severe visual impairment, or cannot physically sign:

1. Impartial Witness Requirement: An impartial witness (an individual independent of the trial, who cannot be unfairly influenced by people involved with the trial) must be present during the entire informed consent discussion.
2. Oral Explanation: The written ICF and any other written information is read aloud and explained to the prospective subject.
3. Freely Given Verbal Consent: The subject orally consents to participate and, if capable, places their mark or thumbprint on the signature line.
4. Witness Attestation & Signature: The impartial witness personally signs and dates the consent form, attesting that:
   • The information in the ICF was accurately explained to, and apparently understood by, the subject.
   • Informed consent was freely given by the subject without coercion.

┌───────────────────────────────────────────────────────────────────────────┐
│              SIGNATURE REQUIREMENTS SUMMARY BY SCENARIO                   │
├───────────────────────────────────────────────────────────────────────────┤
│  1. STANDARD ADULT CONSENT:                                               │
│     • Subject signs & dates ICF                                           │
│     • Person obtaining consent signs & dates ICF                          │
├───────────────────────────────────────────────────────────────────────────┤
│  2. SHORT FORM NON-ENGLISH CONSENT:                                       │
│     • Short Form (Foreign Lang): Subject + Impartial Witness sign/date    │
│     • Summary (English ICF): Person Obtaining + Impartial Witness sign    │
├───────────────────────────────────────────────────────────────────────────┤
│  3. ILLITERATE / VISUALLY IMPAIRED PARTICIPANT (ICH 4.8.9):               │
│     • ICF: Subject (Thumbprint/Mark if able)                              │
│     • ICF: Impartial Witness signs & dates (Attestation of oral reading)  │
│     • ICF: Person obtaining consent signs & dates                         │
└───────────────────────────────────────────────────────────────────────────┘

---

6. Ongoing Consent & Re-Consent Requirements (ICH E6(R3) Annex 1 2.8)

Informed consent does not terminate once the initial document is signed. When new information becomes available that may affect a participant's safety or willingness to continue, re-consent is legally and ethically mandated.

Triggers Requiring Re-Consent:

1. Protocol Amendments: Significant modifications to study procedures, dosing regimens, visit frequency, or pharmacokinetic sampling schedules.
2. New Safety Information / Identified Risks: Emerging Serious Adverse Reactions (SARs), revised toxicities in the updated Investigator's Brochure (IB), or black box warnings on concurrent therapies.
3. Alternative Approved Treatments: Regulatory approval of a new commercial drug that changes standard-of-care alternatives.
4. Pediatric Subject Turning Age of Majority: A minor participant reaching legal adulthood (typically age 18) must be re-consented as an adult.

Operational Workflow for Re-Consent:

┌───────────────────────────────────────────────────────────────────────────┐
│                     RE-CONSENT OPERATIONAL WORKFLOW                       │
├───────────────────────────────────────────────────────────────────────────┤
│  1. Sponsor updates Protocol / IB & drafts Revised ICF                    │
│  2. IRB/IEC reviews and issues written approval of Revised ICF            │
│  3. Site receives IRB-approved Revised ICF with new version date/stamp     │
│  4. Research team presents Revised ICF to active subjects                 │
│     • CRITICAL: Must occur prior to or at the subject's NEXT visit        │
│     • BEFORE any new protocol-amended procedures are performed            │
│  5. Subject & Person Obtaining Consent sign and date Revised ICF          │
│  6. Subject receives copy; comprehensive note documented in source records │
└───────────────────────────────────────────────────────────────────────────┘

Exam Watchout: A site cannot perform new protocol procedures on an active subject under an amended protocol until that subject has been formally re-consented on the newly approved IRB version. If a subject is in long-term safety follow-up and the amendment only affects active dosing, the IRB may approve re-consenting via mail or verbal disclosure, but active interventional subjects must always sign the revised ICF.

---

7. Realistic Clinical Scenario & ACRP-CP Critical Analysis

Scenario: A clinical research coordinator (CRC) is screening patients in an acute care stroke trial. A potential subject arrives who speaks only Cantonese. The site has the IRB-approved English ICF but does not have a Cantonese translated ICF. The subject is accompanied by his adult bilingual daughter. The protocol allows enrollment within a 6-hour therapeutic window. The investigator asks the daughter to translate the English ICF to her father and have the father sign the English ICF, while the daughter signs as the "witness."

ACRP-CP Critical Evaluation & Compliance Breakdown:

1. Regulatory Violation 1 (Improper Document Execution): A subject who cannot read English must never sign an English ICF. Signing a document in a language the subject cannot read is a major regulatory violation.
2. Regulatory Violation 2 (Unqualified / Biased Translator): Using a family member as the official medical interpreter is improper. Family members may filter clinical information, lack medical vocabulary, or exert family pressure. A certified medical interpreter must be utilized.
3. Regulatory Violation 3 (Impartial Witness Defect): A family member is emotionally and personally invested in the subject's care and therefore does not meet the regulatory definition of an impartial witness.
4. Compliant Action Plan:
   • Obtain an IRB-approved Short Form written in Cantonese.
   • Engage a certified Cantonese medical interpreter to orally present the English summary (English ICF).
   • Utilize an impartial witness (independent of the study team, such as a neutral hospital staff member or the certified interpreter) to observe the entire oral discussion.
   • The subject signs the Cantonese Short Form; the Person Obtaining Consent signs the English Summary; the Impartial Witness signs both documents.
   • Provide copies of both documents to the subject and document the entire process in the source notes.